| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/16/2004 | CN1504193A Drug composition containing dioxide fluosulfocytosine, lamivudine and Adefovir dipivoxil |
| 06/16/2004 | CN1504191A Cucurbitacin lipsome preparation method and formulation |
| 06/16/2004 | CN1153777C Process for preparing a charcoal-GM1 complex |
| 06/16/2004 | CN1153770C Substitued nitrogen heterocyclic ring as inhibitors of P38 protein kinase |
| 06/16/2004 | CN1153764C Substituted benzylaminopiperidine compounds |
| 06/16/2004 | CN1153580C Traditional Chinese medicine for treating lymph tuberculosis |
| 06/16/2004 | CN1153570C Method and composition of an oral preparation of itraconazole |
| 06/16/2004 | CN1153510C Vaccination against coccidiosis in ovum |
| 06/15/2004 | US6750253 Aminobenzophenones as inhibitors of il-1β and tnf-α |
| 06/15/2004 | US6750240 Methods of using bis-indolylquinones |
| 06/15/2004 | US6750239 Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750217 Anticancer agents; cardiovascular disorders; kinase inhibitor |
| 06/15/2004 | US6750212 Photochemotherapeutic compositions |
| 06/15/2004 | US6750204 11-C-substituted ketolides |
| 06/15/2004 | US6750199 Antimicrobial sulfonamide derivatives of lipopeptide antibiotics |
| 06/15/2004 | US6750008 Use of peptides for inhibition of human and non-human retroviral, especially hiv, transmission to uninfected cells |
| 06/15/2004 | US6749869 Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| 06/15/2004 | US6749858 Nucleotide sequences coding polypeptide for use in the prevention of streptoccocus infection |
| 06/15/2004 | US6749857 Recombinant dimeric envelope vaccine against flaviviral infection |
| 06/15/2004 | US6749587 Modular infusion device and method |
| 06/15/2004 | CA2285921C Composition and method for treatment of cmv infections |
| 06/10/2004 | WO2004048587A1 β-1,4-MANNOBIOSE-CONTAINING COMPOSITION |
| 06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
| 06/10/2004 | WO2004048512A2 Novel proteins and nucleic acids encoding same |
| 06/10/2004 | WO2004048392A1 Oxazolidinone and / or isoxazoline derivatives as antibacterial agents |
| 06/10/2004 | WO2004048370A1 Antibacterial compounds |
| 06/10/2004 | WO2004048320A1 Biguanide and dihydrotriazine derivatives |
| 06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
| 06/10/2004 | WO2004047861A1 Vaccines against viruses with cationic substances as adjuvants |
| 06/10/2004 | WO2004047812A1 Hollow nanoparticles of protein and drug using the same |
| 06/10/2004 | WO2004047725A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/10/2004 | WO2004032959A3 Methods of treating and preventing neurological symptoms caused by avian reovirus and novel associated characteristics |
| 06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004011647A8 Modified small interfering rna molecules and methods of use |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 06/10/2004 | WO2003089571A3 Ehrlichia canis genes and vaccines |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003061558A9 Glycoconjugate vaccines for use in immune-compromised populations |
| 06/10/2004 | WO2003035049A3 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/10/2004 | WO2002090600A3 A method for regulating immune function in primates using the foxp3 protein |
| 06/10/2004 | US20040110966 2-methylenetetrahydro-2(5H)-furanone derivatives, their preparation from 4-oxovaleric acids, and homo-and copolymers of the furanones |
| 06/10/2004 | US20040110963 Novel hydrazones |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110846 Perylenequinones for use with immunotherapy agents |
| 06/10/2004 | US20040110834 can be used as a medicament, food for special healty uses and a health food that are effective for protection against infection of microorganisms such as pathogenic Escherichia coli such as E. coli or Helicobacter pylori. |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110802 Antibacterial benzoic acid derivatives |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110787 Viricides for treating herpes virus; chemical intermediates synthesis |
| 06/10/2004 | US20040110786 Viricides for treating herpes virus, enzyme inhibitor of a viral DNA polymerase, treating viral diseases |
| 06/10/2004 | US20040110774 HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID); antagonists are antibodies |
| 06/10/2004 | US20040110772 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110740 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-alkyl ester, 4,4-dioxide derivative or solvate; can be mixed with beta-lactam antibiotic |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110718 Anti-HCV nucleoside derivatives |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110704 Decreased or deleted activity of enzyme with modified sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in reducing end; antitumor agents, cardiovascular disorders, autoimmune diseases |
| 06/10/2004 | US20040110695 Phospholipid vesicle having exogenous antigen orpolynucleic acid coding for antigen; adapted to be phagocytosed by antigen presenting cells |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110678 Novel drug delivery system |
| 06/10/2004 | US20040110282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 06/10/2004 | US20040110269 Protection against mycobacterial infections |
| 06/10/2004 | US20040110268 Attenuated Pasteurellaceae virulence genes are identified and used to screen bactericides and produce vaccines which prevent infection |
| 06/10/2004 | US20040110181 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 06/10/2004 | US20040110180 Comprises enzymatic polypeptide for diagnosis, treatment and prevention of cardiovascular, immune system, nervous system, lipid and cell proliferative disorders; drug screening |
| 06/10/2004 | US20040110165 Viral chemokine-antigen fusion proteins |
| 06/10/2004 | US20040109896 Herpes viruse infections of the eyes; aqueous suspension of acyclovir, vinyl acetate-vinyl alcohol copolymer and nonionic surfactant |
| 06/10/2004 | US20040109877 Rna viruses; attenuation influenza virus |
| 06/10/2004 | US20040109875 Pro-apoptotic bacterial vaccines to enhance cellular immune responses |
| 06/10/2004 | US20040109873 Genetic engineering equine herpes virus; genes coding protein |
| 06/10/2004 | US20040109865 Antibody composition-containing medicament |
| 06/10/2004 | CA2840698A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | CA2507468A1 Oxazolidinone and / or isoxazoline derivatives as antibacterial agents |
| 06/10/2004 | CA2498566A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/09/2004 | EP1426382A1 Antiviral human serum albumin |
| 06/09/2004 | EP1426376A1 Process for preparation of carbapenem antibiotics |
| 06/09/2004 | EP1426375A2 Analgesic spiroindole derivatives |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1425409A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 06/09/2004 | EP1425391A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes |
| 06/09/2004 | EP1425389A2 Human antibodies specific for interleukin 15 (il-15) |
| 06/09/2004 | EP1425305A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 06/09/2004 | EP1425304A2 G-csf conjugates |
| 06/09/2004 | EP1425303A2 Use of proteins for the production of a medicament for stimulating the innate non specific immune system |
| 06/09/2004 | EP1425258A2 Hydroxyeicosenoic acid analogs |